Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Most (77.1%) of the IPs found were: inappropriate dose and/or frequency (n = 158) and prescription of a contraindicated drug in CKD (n = 28).Inappropriate prescriptions by the patient’s eGFR: types of IP and drugs more involved in the medication plan of patients with CKDTotal number of IP, n201Number of IP per patient, mean ± SD0.7 ± 1.0Number of IP per patient, n (%) 0139 (50.9) 189 (32.6) 230 (11.0) 311 (4.0) 41 (0.4) 53 (1.1)Patients with any IP, n, (%)134 (49.1)Type of IP, n (%)201 (100.0) Inappropriate dose and/or frequency158 (78.6) Contraindicated drug28 (13.9) Inappropriate presentation (it contains a higher dose/intake than recommended according to the patient’s FGe)15 (7.5)Drugs more involved in IP, n (%)According to ATC code Lipid modifying agents, plain (C10A)45 (22.4) Other analgesics and antipyretics (N02B)44 (21.9) Angiotensin converting enzyme inhibitors, plain (C09A)33 (16.4) Blood glucose lowering drugs, excluding insulins (A10B)19 (9.4) Benzodiazepine derivatives (N05CD)14 (7.0) Preparations inhibiting uric acid production (M04AA)11 (5.5) Mineral supplements: calcium (A12A) plus Vitamin D and analogues (A11CC)5 (2.5) Antidepressants (N06A)5 (2.5) Others25 (12.4)According to active substance with respect to the total IP Paracetamol43 (21.4) Atorvastatin28 (13.9) Enalapril28 (13.9) Fenofibrate15 (7.5) Lormetazepam14 (7.0) Metformin10 (5.0) Allopurinol9 (4.5) Sitagliptin8 (4.0) Others drugs46 (22.8)According to active substance with respect to the total number of patients’ study with the prescribed drug Rosuvastatin2/2 (100.0) Fenofibrate15/16 (93.8) Lormetazepam14/16 (87.5) Alfuzosin4/5 (80.0) Cetirizine3/4 (75.0) Atorvastatin28/48 (58.3) Sitagliptin8/19 (42.1) Enalapril28/79 (35.4) Paracetamol43/125 (34.4) Allopurinol9/49 (18.4) Citalopram5/29 (17.2) Metformin10/59 (16.9)

Source: Prescription’s adequacy. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A retrospective observational study was conducted in two urban primary care centres.

Source: Abstract.

The current prescriptions of the patients were analysed one month after the determination of GFR less than 60 mL/min/1.73m2.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Appropriateness of drug prescriptions in patients with chronic kidney disease in primary care: a double-center retrospective study

Observational study · BMC Primary Care · 2022

Original publication title

Appropriateness of drug prescriptions in patients with chronic kidney disease in primary care: a double-center retrospective study

Sonia Ruiz-Boy; Montserrat Rodriguez-Reyes; Joan Clos-Soldevila; Marina Rovira-Illamola

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Patients with CKD are at increased risk of medication-related problems. It is necessary to implement measures to improve the safety in the prescription of drugs in patients with CKD.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Chronic kidney disease (CKD) is a highly prevalent disease worldwide. A basic pillar for the management of a patient with CKD is the safe use of drugs. Inadequate dosing of medication or contraindicated drugs in renal impairment can lead to negative outcomes. The primary objective was to analyse the drug prescriptions of patients with CKD from two primary care centres to see if they were optimally adapted to the patient's estimated glomerular filtration rate (eGFR).

Source: Background

Abstract: What methods does the paper describe?

A retrospective observational study was conducted in two urban primary care centres. The study period was between September: October 2019. Patients over 18 years of age, with established CKD and with an eGFR less than 60 mL/min/1.73m2 for at least three months were included. Their demographic data (age and sex) and clinical variables such as associated comorbidities, eGFR value were retrospectively registered. Finally, their medication plans were reviewed in order to detect: inappropriate prescribing (IP), defined as an incorrect dose/frequency or contraindicated drug according to the renal function of the patient; nephrotoxic drugs and drugs with a high sodium content.

Source: Methods

Abstract: Results

A total of 273 patients were included. The most common patient profile was an elderly woman, polymedicated, with other concomitant diseases and with mild CKD. Two hundred and one IPs were detected, 13.9% of which were contraindicated drugs. Of all patients, 49.1% had been prescribed at least one IP on their medication plan, 93.8% had some potentially nephrotoxic drug and 8.4% had drugs with a high sodium content prescribed.

Source: Results

Abstract: Conclusions

Patients with CKD are at increased risk of medication-related problems. It is necessary to implement measures to improve the safety in the prescription of drugs in patients with CKD.

Source: Conclusions
Authors’ abstract

Background

Chronic kidney disease (CKD) is a highly prevalent disease worldwide. A basic pillar for the management of a patient with CKD is the safe use of drugs. Inadequate dosing of medication or contraindicated drugs in renal impairment can lead to negative outcomes. The primary objective was to analyse the drug prescriptions of patients with CKD from two primary care centres to see if they were optimally adapted to the patient's estimated glomerular filtration rate (eGFR).

Methods

A retrospective observational study was conducted in two urban primary care centres. The study period was between September: October 2019. Patients over 18 years of age, with established CKD and with an eGFR less than 60 mL/min/1.73m2 for at least three months were included. Their demographic data (age and sex) and clinical variables such as associated comorbidities, eGFR value were retrospectively registered. Finally, their medication plans were reviewed in order to detect: inappropriate prescribing (IP), defined as an incorrect dose/frequency or contraindicated drug according to the renal function of the patient; nephrotoxic drugs and drugs with a high sodium content.

Results

A total of 273 patients were included. The most common patient profile was an elderly woman, polymedicated, with other concomitant diseases and with mild CKD. Two hundred and one IPs were detected, 13.9% of which were contraindicated drugs. Of all patients, 49.1% had been prescribed at least one IP on their medication plan, 93.8% had some potentially nephrotoxic drug and 8.4% had drugs with a high sodium content prescribed.

Conclusions

Patients with CKD are at increased risk of medication-related problems. It is necessary to implement measures to improve the safety in the prescription of drugs in patients with CKD.

Publication and source details

Original title: Appropriateness of drug prescriptions in patients with chronic kidney disease in primary care: a double-center retrospective study

Sonia Ruiz-Boy; Montserrat Rodriguez-Reyes; Joan Clos-Soldevila; Marina Rovira-Illamola

BMC Primary Care · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T21:34:13.986601+00:00

DOI: 10.1186/s12875-022-01931-4 · PMC9747536